Latest Data Confirm Imidacloprid Remains Highly Efficacious After More Than a Decade of use
– New Publication From International Experts Demonstrates Fleas Worldwide
Continue to be Highly Susceptible to Imidacloprid
In a study published online last week in Medical and Veterinary
Entomology, international experts reported the latest data on flea
susceptibility to imidacloprid, revealing that after more than a decade of
widespread use around the world, there is no evidence of resistance to this
The study looked at data compiled between 2002 and 2009 by the
International Flea Susceptibility Monitoring (FSM) programme from monitoring
the more than one thousand samples tested over the past eight years, all were
confirmed to be susceptible to imidacloprid.
“These results are great news for veterinarians and pet owners alike,”
Veterinary Medicine, Auburn University
one of the most widely used active ingredients for flea control in pets,
remains as effective against fleas now as it was when it was first launched.”
Imidacloprid is the key active ingredient in Advantage(R) and related
products developed for the effective control of fleas and other parasites in
The International FSM programme is the first and only monitoring
initiative in the field of companion animal parasites. The FSM initiative
includes a group of internationally renowned, independent researchers who
work together with Bayer Animal Health to monitor the susceptibility of fleas
“In order to prevent resistance to treatments such as imidacloprid,
careful and coordinated monitoring is essential in order to detect as early
as possible any potential shifts in susceptibility. The FSM programme is
unique in terms of geographical scale and duration. It is an excellent
example of a pharmaceutical company collaborating with academic organisations
to ensure the efficacy and safety of its products,” said
Principal Scientist, Rothamsted Research, Harpenden, UK.
Bayer Animal Health supported the initiation of the FSM, in partnership
with an international panel of experts, in order to monitor the
susceptibility of flea populations to imidacloprid, the active ingredient of
Advantage(R). “We are delighted to see that, once again, the data from the
FSM programme show that veterinary professionals and pet owners can continue
to trust Advantage(R) to provide effective, reliable flea control for
companion animals,” said
Bayer Animal Health.
About the Flea Susceptibility Monitoring (FSM) program
The FSM is a large-scale international program based on a monitoring
methodology which utilises flea eggs collected from the field in the US,
of veterinarians and the samples analysed in four investigating laboratories
based in three countries. The FSM was set up in 1999 and to date has not
detected any reduced susceptibility to imidacloprid. A dedicated team of 15
people including independent experts in veterinary parasitology, entomology
and molecular biology, in addition to Bayer personnel, work together to
manage the FSM program.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the
fields of health care, nutrition and high-tech materials. Bayer HealthCare, a
subgroup of Bayer AG with annual sales of more than
is one of the world’s leading, innovative companies in the healthcare and
medical products industry and is based in Leverkusen,
combines the global activities of the Animal Health, Consumer Care, Medical
Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and
manufacture products that will improve human and animal health worldwide.
Bayer HealthCare has a global workforce of 53.400 employees and is
represented in more than 100 countries.
Find more information at http://www.bayerhealthcare.com.
With a turnover of
Division is one of the world’s leading manufacturers of veterinary drugs. The
division manufactures and markets more than 100 different veterinary drugs
and care products for livestock and companion animals.
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. These
factors include those discussed in our annual and interim reports to the
Frankfurt Stock Exchange and in our reports filed with the U.S. Securities
and Exchange Commission (including our Form 20-F). The company assumes no
liability whatsoever to update these forward-looking statements or to confirm
them to future events or developments.
Contact: Kathrin Statz, +49-2173-384019 email@example.com
SOURCE Bayer HealthCare